Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

by Pérez Manghi, Federico C , Liu, Bing , Rosenstock, Julio , Frías, Juan P , Davies, Melanie J , Fernández Landó, Laura , Cui, Xuewei , Bergman, Brandon K , Brown, Katelyn

in Adverse events / Agonists / Antidiabetics / Blood Glucose - analysis / Body weight / Cardiology / Chronic Kidney Disease / Coronary Disease / Diabetes / Diabetes mellitus (non-insulin dependent) / Diabetes Mellitus, Type 2 - blood / Diabetes Mellitus, Type 2 - drug therapy / Diabetic retinopathy / Diarrhea / Dosage / Dose-Response Relationship, Drug / Drug Administration Schedule / Drug Therapy, Combination / Endocrinology / Fasting / Female / Gastric Inhibitory Polypeptide - administration & dosage / Gastric Inhibitory Polypeptide - adverse effects / GIP protein / GLP-1 receptor agonists / Glucagon / Glucagon-like peptide 1 / Glucagon-Like Peptide-1 Receptor - agonists / Glucagon-Like Peptides - administration & dosage / Glucagon-Like Peptides - adverse effects / Glucose / Glycated Hemoglobin A - analysis / Heart attacks / Hemoglobin / Humans / Hypoglycemia / Hypoglycemic Agents - administration & dosage / Hypoglycemic Agents - adverse effects / Hypoglycemic Agents - therapeutic use / Incretins - therapeutic use / Injections, Subcutaneous / Insulin resistance / Kidney diseases / Male / Metformin - therapeutic use / Middle Aged / Myocardial Infarction / Nausea / Nausea - chemically induced / Nephrology / Patients / Polypeptides / Statistical analysis / Vomiting / Weight control / Weight Loss - drug effects

2021

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

by Pérez Manghi, Federico C , Liu, Bing , Rosenstock, Julio , Frías, Juan P , Davies, Melanie J , Fernández Landó, Laura , Cui, Xuewei , Bergman, Brandon K , Brown, Katelyn

2021

Confirm

Do you wish to request the book?

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

by Pérez Manghi, Federico C , Liu, Bing , Rosenstock, Julio , Frías, Juan P , Davies, Melanie J , Fernández Landó, Laura , Cui, Xuewei , Bergman, Brandon K , Brown, Katelyn

2021

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Pérez Manghi, Federico C,

Liu, Bing,

Rosenstock, Julio,

Frías, Juan P,

Davies, Melanie J,

Fernández Landó, Laura,

Cui, Xuewei,

Bergman, Brandon K,

Brown, Katelyn

2021

Overview

This open-label, 40-week, phase 3 trial assessed the efficacy and safety of tirzepatide, a weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist under development for type 2 diabetes. Tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adverse events

/ Agonists

/ Antidiabetics

/ Blood Glucose - analysis

/ Body weight

/ Cardiology

/ Chronic Kidney Disease